Skip to main content
Premium Trial:

Request an Annual Quote

Correlogic, USU and Jackson Foundation to Develop Prostate Cancer Dx

NEW YORK, May 6 (GenomeWeb News) - Correlogic Systems, the Uniformed Services University of the Health Sciences, and the Henry M. Jackson Foundation for the Advancement of Military Medicine intend to co-develop a blood test for the detection of prostate cancer based on the company's protein pattern-recognition approach, the firm said today.


Two concurrent studies will involve up to 2,000 men with prostate cancer. The first study will use Correlogic's ProteomeDx pattern recognition technology to try to develop a blood test for prostate cancer detection that is more effective thanthe current prostate specific antigen test.


With the current PSA test, approximately 75 percent of men who test positive end up undergoing unnecessary prostate biopsies, according to Correlogic.


In the second study, researchers will try to use the technology to try to develop a test to distinguish between indolent and aggressive prostate cancer.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.